WEREWOLF THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $307.00 thousand for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $89.00K, a 53.89% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $218.00K, a 15.96% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $206.00K, a 16.38% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $198.00K, a 17.16% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.57M, a 12.02% increase from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.41M, a 170.91% increase from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $519.00K, a 17.22% decline from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $627.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $89.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | $307.00K S-4 · filed 2026-09-22 | $513.00K derived: sum of 3 quarters · filed 2026-09-22 | $711.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | $218.00K 10-Q · filed 2026-05-07 | $424.00K derived: sum of 2 quarters · filed 2026-09-22 | $622.00K derived: sum of 3 quarters · filed 2026-09-22 | $815.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | $206.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $404.00K derived: sum of 2 quarters · filed 2026-09-22 | $597.00K derived: sum of 3 quarters · filed 2026-09-22 | $785.00K S-4 · filed 2026-09-22 |
| 2025-09-30 | $198.00K derived: 10-Q 9 month − S-4 6 month · filed 2025-11-04 | $391.00K derived: sum of 2 quarters · filed 2026-09-22 | $579.00K 10-Q · filed 2025-11-04 | $756.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $193.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | $381.00K S-4 · filed 2026-09-22 | $558.00K derived: sum of 3 quarters · filed 2026-09-22 | $727.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | $188.00K 10-Q · filed 2026-05-07 | $365.00K derived: sum of 2 quarters · filed 2026-09-22 | $534.00K derived: sum of 3 quarters · filed 2026-09-22 | $699.00K derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | $177.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $346.00K derived: sum of 2 quarters · filed 2026-09-22 | $511.00K derived: sum of 3 quarters · filed 2026-09-22 | $887.00K S-4 · filed 2026-09-22 |
| 2024-09-30 | $169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $334.00K derived: sum of 2 quarters · filed 2025-11-04 | $710.00K 10-Q · filed 2025-11-04 | $1.07M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $541.00K 10-Q · filed 2025-08-14 | $904.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.44M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $376.00K 10-Q · filed 2025-05-08 | $739.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.28M derived: sum of 3 quarters · filed 2025-05-08 | $1.61M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $363.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $900.00K derived: sum of 2 quarters · filed 2025-03-11 | $1.24M derived: sum of 3 quarters · filed 2025-03-11 | $1.57M 10-K · filed 2025-03-11 |
| 2023-09-30 | $537.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $876.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.21M 10-Q · filed 2024-11-07 | $1.35M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $339.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $675.00K 10-Q · filed 2024-08-08 | $816.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.12M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $336.00K 10-Q · filed 2024-05-03 | $477.00K derived: sum of 2 quarters · filed 2024-05-03 | $781.00K derived: sum of 3 quarters · filed 2024-05-03 | $1.36M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $445.00K derived: sum of 2 quarters · filed 2024-03-07 | $1.02M derived: sum of 3 quarters · filed 2024-03-07 | $1.41M 10-K · filed 2024-03-07 |
| 2022-09-30 | $304.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $882.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.26M 10-Q · filed 2023-11-14 | $1.28M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $578.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $961.00K 10-Q · filed 2023-08-10 | $972.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.14M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $383.00K 10-Q · filed 2023-05-11 | $394.00K derived: sum of 2 quarters · filed 2023-05-11 | $566.00K derived: sum of 3 quarters · filed 2023-05-11 | $736.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $183.00K derived: sum of 2 quarters · filed 2023-03-23 | $353.00K derived: sum of 3 quarters · filed 2023-03-23 | $519.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $172.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $342.00K derived: sum of 2 quarters · filed 2022-11-10 | $508.00K 10-Q · filed 2022-11-10 | $827.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $170.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $336.00K 10-Q · filed 2022-08-11 | $655.00K derived: sum of 3 quarters · filed 2022-08-11 | $655.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $166.00K 10-Q · filed 2022-05-10 | $485.00K derived: sum of 2 quarters · filed 2022-05-10 | $485.00K derived: sum of 3 quarters · filed 2022-05-10 | $641.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $319.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $319.00K derived: sum of 2 quarters · filed 2022-03-24 | $475.00K derived: sum of 3 quarters · filed 2022-03-24 | $627.00K 10-K · filed 2022-03-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $156.00K derived: sum of 2 quarters · filed 2021-11-10 | $308.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $156.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $308.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $152.00K 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |